Study of more than 26,000 patients across 21 community oncology practices found statistically significant higher treatment persistence among patients who viewed treatment-specific education

Nashville, TN – October 13, 2026 – Patients who viewed personalized, treatment-specific education when starting cancer therapy had 8 percent higher treatment persistence after six monthscompared with patients who did not view educational content, according to new research from OneOncology presented today at the 2026 ASCO Quality Care Symposium.

The study, “Improved Treatment Persistency Among Patients Who View Personalized Education at Treatment Initiation,” evaluated more than 26,000 patients initiating one of nine cancer therapies across 21 community oncology practices in the OneOncology network. Researchers examined treatment persistence over a 168-day follow-up period across both oral and intravenous therapies. Fifty-eight percent of patients that engaged with patient education remained on therapy at 168 days, compared with 50.5 percent that did not engage with education. Improved treatment adherence percentages for patients receiving and engaging with educational content was consistent compared to patients that did not receive education and those that received and did not engage with the educational content.

“Patients are asked to absorb an enormous amount of information when they begin cancer treatment, often at a time when they are anxious, overwhelmed and trying to understand what comes next,” said Davey Daniel, M.D., Chief Medical Officer, OneOncology, who was the lead author on the research. “Patient education needs to be more than information on a page. It needs to be timely, relevant to the treatment the patient is receiving, and easy to access. These clinically meaningful findings suggest that engaging patients with personalized education at the start of treatment may play an important role in helping them stay on therapy.”

The research examined whether drug-specific educational content delivered post-prescription through the patients’ clinic patient portal could support patients' understanding and self-management of newly initiated cancer therapies. The educational content was delivered through a OneOncology subsidiary, Navigating Care’s patient portal and patient education platform, and was customized to each treatment. Navigating Care partners with oncology manufacturers to deliver clinically relevant and timely post-prescription education to patients throughout their treatment journey.

Among the patients evaluated, those who viewed the treatment-specific education demonstrated higher treatment persistence than those who did not view the content. The association was observed across routes of administration and across the nine therapies evaluated.

The findings highlight the potential value of integrating patient education into the treatment experience rather than treating education as a separate component of care. For community oncology practices, delivering relevant information through an established patient engagement channel may provide an opportunity to help patients better understand and manage their treatment from the outset.

The research adds to growing evidence that patient engagement and education can be important components of high-quality cancer care, particularly at moments when patients are asked to manage new treatment regimens.

To the view the abstract, visit ASCO.org and to contact OneOncology, email ehoffman@oneoncology.com.